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General experimental procedures 
The melting points were determined on a Buchi M-560 melting point apparatus and are 
uncorrected. Infrared (IR) spectra were recorded on Shimadzu FT-IR spectrophotometer in the 
range of 200 cm-1 to 4000 cm-1. All the samples were run on a sodium chloride plate as a liquid 
film. Absorption maxima were recorded in wave numbers (cm-1). Proton nuclear magnetic 
resonance (1H NMR) spectra were recorded on BRUCKER–ACF-300 (300 MHz). Carbon 
nuclear magnetic resonance (13C NMR) spectra were recorded on BRUCKER-ACF-300 (75 
MHz). All chemical shifts are reported in parts per million (δ) relative to tetramethylsilane 
(TMS), reference to the chemical shifts of residual solvent resonances (1H and 13C NMR). 
Coupling constants are given in Hz. All samples are run in deutero-chloroform (CDCl3) and 
DMSO. The FAB mass spectra were recorded at 6000 Mass Spectrometed data systems using 
Argon/Xenon (6KV, 10mA) as the FAB gas. The accelerating voltage was 10 KV and the 
spectra were recorded at room temperature. 
General procedure for the synthesis of 2-thioxo-bezochromenopyrimidin-4-ones (4a-4o)  
 In a typical experiment, p-nitrobenzaldehyde 3 (1.0 mmol), β-napthol 2 (0.144g, 1.0 mmol), 
thiobarbituric acid 1 (1.0 mmol) and CPC (0.015 mmol %) were taken in a round bottom flask 
using water (2.5 mL) and acetonitrile (2.5 mL) as solvent in 1:1 ratio. The reaction mixture was 
refluxed and the progress of the reaction was monitored by TLC. After completion of reaction (8 
h), the solid obtained was collected by filtration and washed successively with water (3 x 10 mL) 
and with acetonitrile (3 x 5 mL). The crude product was recrystallized from ethanol to afford the 
pure compound 4 which required no further purification. 
2-Thioxo-5-(4-nitrophenyl)-benzo[f]chromeno[2,3-d]pyrimidin-4-one (4a). Yellow solid; m.p. 
207-2100C; IR (KBr): νmax 3541, 1651, 1537, 1445, 1350, 1198, 1132, 1015, 849 cm-1; 1H NMR 
(DMSO-d6, 300 MHz): ∂ 5.70 (s, 1H), 6.72 (m, 1H), 6.85 (m, 1H), 7.01 (d, 2H, J=7.6 Hz), 7.24 
(m, 4H), 7.67 (d, 2H, J=7.6 Hz), 10.90 (br s, 1H), 11.20 (br s, 1H); 13C NMR (DMSO-d6, 75 
MHz): ∂ 173.6, 152.9, 145.7, 128.3, 123.5, 95.6, 31.6; Anal. Calcd. for C21H13N3O4S: C 62.52, H 
3.25, N 10.42; Found: C 62.83, H 3.64, N 10.54. 
2-Thioxo-5-(4-chlorophenyl)-benzo[f]chromeno[2,3-d]pyrimidin-4-one (4b). White solid; m.p: 
198-2030C; IR (KBr): νmax 3524, 1660, 1537, 1443, 1359, 1201, 1134, 1013, 866 cm-1; 1H NMR 
(DMSO-d6, 300 MHz): ∂ 5.80 (s, 1H), 6.97-7.22 (m, 10H), 11.32 (br s, 1H), 11.69 (br s, 1H); 13C 
NMR (DMSO-d6, 75 MHz): ∂173.4, 164.0, 163.0, 142.7, 129.8, 128.9, 128.0, 96.0, 30.6; HRMS 
(EI) cald. 393.0464; found 393.0478. Anal. Calcd. for C21H13ClN2O2S: C 64.20, H 3.34, N 7.13; 
Found: C 64.13, H 3.75, N 7.37. 
2-Thioxo-5-(1H-indol-3-yl)-benzo[f]chromeno[2,3-d]pyrimidin-4-one (4c). White solid; m.p: 
188-1920C; IR (KBr): νmax 3538, 1655, 1528, 1377, 1277, 1213, 1157 cm-1; 1H NMR (DMSO-d6, 
300 MHz): ∂ 5.80 (s, 1H), 6.97-7.22 (m, 10H), 12.28 (br s, 1H), 12.32 (br s, 1H), 13.01 (br s, 
1H); 13C NMR (DMSO-d6, 75 MHz): ∂ 178.2, 163.3, 161.5, 145.1, 141.5, 137.1,129.5, 124.5, 
123.6, 118.4, 113.9, 112.9, 109.2, 29.5; Anal. Calcd. for C23H15N3O2S: C 69.50, H 3.80, N 
10.57; Found: C 69.65, H 3.98, N 10.86. 
2-Thioxo-5-(3-hydroxynaphthalen-1-yl)-benzo[f]chromeno[2,3-d]pyrimidin-4-one (4d). White 
solid; m.p: 195-1980C; IR (KBr): νmax 3452, 3032, 1678, 1564, 1458, 1211, 1138, 814 cm-1; 1H 
NMR (DMSO-d6, 300 MHz): ∂ 5.56 (s, 1H), 7.15 (m, 2H), 7.22 (m, 2H), 7.55 (m, 2H), 7.60 (m, 
2H), 7.88 (m, 2H), 8.22 (m, 2H), 11.55 (br s, 1H), 12.20 (br s, 1H); 13C NMR (DMSO-d6, 75 
MHz): ∂ 174.9, 173.5, 160.3, 156. 8, 148.3, 131.4, 129.8, 128.0, 126.6, 126.5, 123.1, 119.1, 
109.1, 43.2, 29.6; Anal. Calcd. for C25H16N2O3S: C 70.74, H 3.80, N 6.60; Found: C 70.46, H 
3.62, N 6.33. 
2-Thioxo-5-(4-N,N-dimethylanilino)-benzo[f]chromeno[2,3-d]pyrimidin-4-one (4e). White solid; 
m.p: 205-2080C; IR (KBr): νmax 3457, 3119, 1634, 1537, 1495, 1373, 1194, 1142, 1011 cm-1; 1H 
NMR (DMSO-d6, 300 MHz): ∂ 3.00 (s, 3H), 3.02 (s, 3H), 5.90 (s, 1H), 6.75 (m, 2H), 7.22 (m, 
2H), 7.40 (m, 2H), 8.22 (m, 2H), 8.48 (m, 2H), 11.98 (br s, 1H), 12.05 (br s, 1H); 13C NMR 
(DMSO-d6, 75 MHz): ∂ 178.0, 173.5, 163.5, 161.0, 156.7, 155.3, 140.3, 128.6, 120.9, 112.0, 
109.8, 95.9, 46.1, 30.9; Anal. Calcd. for C23H19N3O2S: C 68.81, H 4.77, N 10.47; Found: C 
68.69, H 4.54, N 10.23. 
2-Thioxo-5-(4-carbaldehydophenyl)-benzo[f]chromeno[2,3-d]pyrimidin-4-one (4f). White solid; 
m.p: 201-2030C; IR (KBr): νmax 3522, 3148, 1670, 1574, 1518, 1433, 1298, 1207, 1148 cm-1; 1H 
NMR (DMSO-d6, 300 MHz): ∂ 4.50 (s, 1H), 5.90 (s, 1H), 7.12-8.25 (m, 10H), 11.62 (br s, 1H), 
12.25 (br s, 1H), 12.42 (br s, 1H); 13C NMR (DMSO-d6, 75 MHz): ∂ 178.4, 173.5, 162.5, 145.2, 
132.7, 128.6, 61.3, 29.6; Anal. Calcd. for C22H14N2O3S: C 68.38, H 3.65, N 7.25; Found: C 
68.61, H 3.48, N 7.46. 
2-Thioxo-5-propyl-benzo[f]chromeno[2,3-d]pyrimidin-4-one (4g). White solid; m.p: 188-1920C; 
IR (KBr): νmax 3178, 1686, 1582, 1522, 1316, 1165 cm-1; 1H NMR (DMSO-d6, 300 MHz): ∂ 0.82 
(m, 3H), 1.18 (m, 2H), 2.28 (m, 2H), 5.78 (m, 1H), 7.12 (m, 2H), 7.32-7.45 (m, 2H), 7.65-7.72 
(m, 2H), 11.98 (br s, 1H), 12.05 (br s, 1H); 13C NMR (DMSO-d6, 75 MHz): ∂ 178.2, 157.3, 
145.5, 135.3, 129.8, 128.6, 128.0, 126.6, 126.5, 123.1, 119.1, 109.1, 31.8, 29.6, 22.4, 14.5; Anal. 
Calcd. for C24H20N2O2S: C 71.98, H 5.03, N 6.99; Found: C 71.87, H 4.92, N 6.55. 
2-Thioxo-5-(2,4-dimethoxyphenyl)-benzo[f]chromeno[2,3-d]pyrimidin-4-one (4h). White solid; 
m.p: 185-1870C; IR (KBr): νmax 3181, 1688, 1576, 1543, 1495, 1379, 1260, 1175, 1034, 949 cm-
1; 1H NMR (DMSO-d6, 300 MHz): ∂ 3.73 (s, 3H), 3.85 (s, 3H), 4.56 (s, 1H), 7.08-7.23 (m, 5H), 
7.40-8.13 (m, 4H), 12.34 (br s, 1H), 12.48 (br s, 1H); 13C NMR (DMSO-d6, 75 MHz): ∂ 178.5, 
161.7, 159.4, 155.2, 154.1, 150.1, 145.4, 129.2, 128.0, 126.1, 125.9, 122.6, 121.6, 121.2, 118.4, 
117.0, 56.3, 55.5, 28.8; Anal. Calcd. for C23H18N2O4S: C 66.01, H 4.34, N 6.69; Found: C 66.23, 
H 4.62, N 6.83. 
2-Thioxo-5-(3-nitrophenyl)-benzo[f]chromeno[2,3-d]pyrimidin-4-one (4i). White solid; m.p: 
185-1870C; IR (KBr): νmax 3181, 1688, 1576, 1543, 1495, 1379, 1260, 1175, 1034, 949 cm-1; 1H 
NMR (DMSO-d6, 300 MHz): ∂ 5.75 (s, 1H), 7.38-7.43 (m, 4H), 7.65 (d, J = 8.4 Hz, 1H), 7.88-
8.07 (m, 4H), 8.17 (d, J = 9.2 Hz, 1H), 12.14 (br s, 1H), 12.38 (br s, 1H); 13C NMR (DMSO-d6, 
75 MHz): ∂ 173.1, 163.8, 153.6, 148.7, 138.4, 133.8, 131.3, 125.6, 123.1, 116.9, 89.4, 33.8; 
Anal. Calcd. for C21H13N3O4S: C 62.52, H 3.25, N 10.42; Found: C 62.74, H 3.42, N 10.61. 
2-Thioxo-5-(4-methoxyphenyl)-benzo[f]chromeno[2,3-d]pyrimidin-4-one (4j). White solid; m.p: 
185-1870C; IR (KBr): νmax 3181, 1688, 1576, 1543, 1495, 1379, 1260, 1175, 1034, 949 cm-1; 1H 
NMR (DMSO-d6, 300 MHz): ∂ 3.63 (s, 3H), 5.56 (s, 1H), 6.82 (d, J = 8.2 Hz, 2H), 7.11-7.26 (m, 
4H), 7.32-7.88 (m, 4H), 11.34 (br s, 1H), 12.18 (br s, 1H); 13C NMR (DMSO-d6, 75 MHz): ∂ 
177.8, 164.3, 158.2, 153.8, 150.4, 146.7, 132.2, 131.0, 129.8, 129.2, 127.6, 125.8, 124.2, 118.7, 
114.5, 89.6, 56.3, 55.6, 33.8; Anal. Calcd. for C22H16N2O3S: C 68.02, H 4.15, N 7.21; Found: C 
68.17, H 4.27, N 7.45. 
1,3-Dimethyl-2-thioxo-5-phenyl-benzo[f]chromeno[2,3-d]pyrimidin-4-one (4k). White solid; 
m.p: 215-2170C; IR (KBr): νmax 2978, 1688, 1584, 1526, 1322, 1095 cm-1; 1H NMR (DMSO-d6, 
300 MHz): ∂ 3.32 (s, 3H), 3.48 (s, 3H), 5.72 (m, 1H), 7.12-7.28 (m, 4H), 7.36-7.44 (m, 5H), 7.72 
(m, 2H); 13C NMR (DMSO-d6, 75 MHz): ∂ 175.1, 162.2, 152.3, 147.5, 135.8, 131.8, 130.6, 
128.4, 126.9, 126.3, 124.7, 123.1, 119.3, 116.2, 91.8, 36.6, 28.4, 27.5; Anal. Calcd. for 
C23H18N2O2S: C 71.48, H 4.69, N 7.25; Found: C 71.62, H 4.96, N 7.48. 
1,3-Dimethyl-2-thioxo-5-(4-nitrophenyl)-benzo[f]chromeno[2,3-d]pyrimidin-4-one (4l). White 
solid; m.p: 272-2750C; IR (KBr): νmax 2924, 1678, 1588, 1516, 1338, 1227, 1118 cm-1; 1H NMR 
(DMSO-d6, 300 MHz): ∂ 3.28 (s, 3H), 3.53 (s, 3H), 5.84 (m, 1H), 7.38 (d, J = 9.1 Hz, 1H), 7.42-
7.48 (m, 2H), 7.53 (d, J = 8.8 Hz, 2H), 7.78-8.02 (m, 4H), 8.14 (d, J = 9.2 Hz, 1H); 13C NMR 
(DMSO-d6, 75 MHz): ∂ 175.4, 161.8, 152.6, 150.3, 147.2, 139.7, 131.2, 130.4, 128.7, 127.3, 
125.8, 124.1, 123.5, 118.1, 116.6, 90.4, 36.2, 29.3, 28.4; Anal. Calcd. for C23H17N3O4S: C 64.03, 
H 3.97, N 9.74; Found: C 64.21, H 4.02, N 9.88. 
1,3-Dimethyl-2-thioxo-5-(4-methoxyphenyl)-benzo[f]chromeno[2,3-d]pyrimidin-4-one (4m). 
White solid; m.p: 257-2590C; IR (KBr): νmax 3032, 2962, 1686, 1574, 1528, 1432, 1328, 1205 
cm-1; 1H NMR (DMSO-d6, 300 MHz): ∂ 3.30 (s, 3H), 3.58 (s, 3H), 3.88 (s, 3H), 5.77 (m, 1H), 
6.78 (d, J = 8.9 Hz, 2H), 7.22 (d, J = 8.8 Hz, 2H), 7.34-7.48 (m, 3H), 7.68-7.82 (m, 2H), 8.10 (d, 
J = 8.2 Hz, 1H); 13C NMR (DMSO-d6, 75 MHz): ∂ 174.8, 161.4, 159.4, 158.1, 153.2, 135.6, 
133.4, 129.8, 128.3, 127.8, 125.3, 123.1, 122.5, 118.2, 116.3, 82.1, 56.4, 29.2, 28.7, 28.1;  
Anal. Calcd. for C24H20N2O3S: C 69.21, H 4.84, N 6.73; Found: C 69.04, H 4.92, N 6.84. 
1,3-Dimethyl-2-thioxo-5-(4-methylphenyl)-benzo[f]chromeno[2,3-d]pyrimidin-4-one (4n). White 
solid; m.p: 212-2150C; IR (KBr): νmax 3011, 2954, 1692, 1635, 1483, 1344, 1216 cm-1; 1H NMR 
(DMSO-d6, 300 MHz): ∂ 2.19 (s, 3H), 3.31 (s, 3H), 3.64 (s, 3H), 5.69 (m, 1H), 6.98 (d, J = 8.4 
Hz, 2H), 7.19 (d, J = 8.4 Hz, 2H), 7.31-7.51 (m, 3H), 7.70-7.84 (m, 2H), 7.96 (d, J = 8.2 Hz, 
1H); 13C NMR (DMSO-d6, 75 MHz): ∂ 175.1, 161.6, 152.8, 147.3, 140.2, 135.9, 132.1, 130.3, 
129.3, 128.6, 127.5, 125.3, 124.4, 122.5, 117.8, 116.5, 91.3, 36.2, 29.4, 28.2, 20.7; Anal. Calcd. 
for C24H20N2O2S: C 71.98, H 5.03, N 6.99; Found: C 71.83, H 5.31, N 7.07. 
1,3-Dimethyl-2-thioxo-5-(4-chlorophenyl)-benzo[f]chromeno[2,3-d]pyrimidin-4-one (4o). White 
solid; m.p: 250-2520C; IR (KBr): νmax 3054, 2958, 1690, 1650, 1583, 1474, 1211 cm-1; 1H NMR 
(DMSO-d6, 300 MHz): ∂ 3.33 (s, 3H), 3.56 (s, 3H), 5.71 (m, 1H), 7,12 (d, J = 8.4 Hz, 2H), 7.33 
(d, J = 8.4 Hz, 2H), 7.38-7.48 (m, 3H), 7.75-7.80 (m, 2H), 8.06 (d, J = 8.5 Hz, 1H); 13C NMR 
(DMSO-d6, 75 MHz): ∂ 174.8, 161.9, 152.2, 150.3, 147.3, 142.4, 133.2, 131.7, 130.8, 129.4, 
128.5, 127.8, 125.6, 123.8, 116.8, 116.1, 90.6, 35.7, 29.0, 28.4; Anal. Calcd. for C23H17ClN2O2S: 
C 65.63, H 4.07, N 6.66; Found: C 65.46, H 4.16, N 6.96. 
Antioxidant assay 
Determination of DPPH free radical scavenging activity is based on the reduction of 
methanolic DPPH in the presence of a hydrogen donating antioxidant. Used as a reagent, DPPH 
evidently offers a convenient and accurate method for titrating the oxidizable groups of natural 
or synthetic antioxidants. The adsorption and intense violet DPPH solution was reduced by an 
antioxidant compound. Lowering absorbance of the reaction mixture inferred higher free-radical 
scavenging effect. Each compound (3ml. at 0.025g/ml) was mixed with DPPH (Sigma) solution 
(45µg/ml) in HPLC grade methanol (Merck), vortexed well at room temperature and was left 
standing for 10 mins exactly and the absorbance was measured at 517 nm 
spectrophotometrically. A solution of BHT (Butylated hydroxy toluene, Sigma) of 125 µg/ml in 
MeOH was used as reference and the methanol without DPPH as a blank solution. Radical 
scavenging activity was calculated on percentage basis using the following equation,  
 
        % Scavenging activity = (A0 – A10)/ (R0 – R10) × 100,  
 
where, A0 and A10 are the absorbance values of (DPPH + Sample) solution at 0 min. and 10 min. 
respectively. R0 and R10 are the absorbance values of (DPPH + BHT) solution at 0 min. and 10 
min. respectively.  
The results indicated that the tested compounds contained antioxidants which reduced the 
stable DPPH free radical to the corresponding yellow coloured diphenyl-picrylhydrazine. The 
antioxidant activity of the compound was expressed as IC50. The IC50 value was defined as the   
which was graphically determined from the trend line of the curve of percent inhibition (Y-axis) 
against concentration (µg/mL) (X-axis), where the straight line form the 50% inhibition on the 
Y-axis intersected the trend line gave the IC (µg/mL) on the X-axis. 
Cytotoxicity assay 
Synthesized compounds (4a-4o) were tested for cytotoxic activity against HEPG2 cells. 
Each compound was dissolved with DMSO and diluted with water to obtain a concentration of 
20 mM. They were incubated with the cells for 72 h. The negative control received the same 
amount of DMSO (0.005% in the highest concentration). The cell viability was determined by 
reduction of the yellow dye 3-(4,5-dimethyl-2-thiazol)- 2,5-diphenyl-2H-tetrazolium bromide 
(MTT) to a blue formazan product after 48 h. In brief, the cells were seeded in a 96-well plate at 
a cell concentration of 1 x 104 cell per well in 100 µL of growth medium and fresh medium 
containing different concentrations of the test sample was added after 24 h of seeding. Serial 
twofold dilution of the tested chemical compound was added to confluent cell monolayers 
dispensed into 96-well, flat-bottomed microtiter plates using a multichannel pipette. The 
microtiter plates were incubated at 37oC in a humidified incubator with 5% CO2 for a period of 
48 h. Three wells were used for each concentration of the test sample. Control cells were 
incubated without test sample and with or without DMSO. The low percentage of DMSO present 
in the wells (maximal 0.1%) was found not to affect the experiment. After incubation of the cells 
for 24 h at 37oC, various concentrations of each sample (50, 25, 12.5, 6.25, 3.125 & 1.56 µg) 
were added, and the incubation was continued for 48 h and viable cell yield was determined by a 
colorimetric method. After the end of the incubation period, media were aspirated and the crystal 
violet solution (1%) was added to each well for at least 30 min. The stain was removed and the 
plates were rinsed using tap water until all excess stain was removed. Glacial acetic acid (30%) 
was then added to all wells and mixed thoroughly, and then the absorbances of the plates were 
measured after gently shaking on microplate reader, using a test wavelength of 490 nm. All 
results were corrected for background absorbance detected in wells without added stain. Treated 
samples were compared with the cell control in the absence of the tested compounds. All 























Figure S3. 13C  NMR spectrum of 4a 
 
 





Figure S5. 1H NMR spectrum of 4b 
 
 











Figure S8. IR spectrum of 4c 
 
 






















Figure S13. 13C NMR spectrum of 4e 
 
 
 
 
